1. Home
  2. TVRD vs TDF Comparison

TVRD vs TDF Comparison

Compare TVRD & TDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • TDF
  • Stock Information
  • Founded
  • TVRD 2017
  • TDF 1994
  • Country
  • TVRD United States
  • TDF Singapore
  • Employees
  • TVRD N/A
  • TDF N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • TDF Finance/Investors Services
  • Sector
  • TVRD Health Care
  • TDF Finance
  • Exchange
  • TVRD Nasdaq
  • TDF Nasdaq
  • Market Cap
  • TVRD 246.5M
  • TDF 244.7M
  • IPO Year
  • TVRD N/A
  • TDF N/A
  • Fundamental
  • Price
  • TVRD $28.34
  • TDF $9.47
  • Analyst Decision
  • TVRD Strong Buy
  • TDF
  • Analyst Count
  • TVRD 2
  • TDF 0
  • Target Price
  • TVRD $52.00
  • TDF N/A
  • AVG Volume (30 Days)
  • TVRD 48.4K
  • TDF 79.2K
  • Earning Date
  • TVRD 05-13-2025
  • TDF 01-01-0001
  • Dividend Yield
  • TVRD N/A
  • TDF N/A
  • EPS Growth
  • TVRD N/A
  • TDF N/A
  • EPS
  • TVRD N/A
  • TDF N/A
  • Revenue
  • TVRD N/A
  • TDF N/A
  • Revenue This Year
  • TVRD N/A
  • TDF N/A
  • Revenue Next Year
  • TVRD N/A
  • TDF N/A
  • P/E Ratio
  • TVRD N/A
  • TDF N/A
  • Revenue Growth
  • TVRD N/A
  • TDF N/A
  • 52 Week Low
  • TVRD $8.13
  • TDF $7.15
  • 52 Week High
  • TVRD $34.31
  • TDF $10.62
  • Technical
  • Relative Strength Index (RSI)
  • TVRD N/A
  • TDF 48.70
  • Support Level
  • TVRD N/A
  • TDF $9.48
  • Resistance Level
  • TVRD N/A
  • TDF $9.70
  • Average True Range (ATR)
  • TVRD 0.00
  • TDF 0.13
  • MACD
  • TVRD 0.00
  • TDF -0.02
  • Stochastic Oscillator
  • TVRD 0.00
  • TDF 6.67

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

Share on Social Networks: